MicroRNAs As Emerging Biomarkers and Therapeutic Targets for Pancreatic Cancer

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2014 Aug 30

PMID 25170204

Citations 20

Authors

Marion Gayral

Sebastien Jo

Naima Hanoun

Alix Vignolle-Vidoni

Hubert Lulka

Yannick Delpu

Aline Meulle

Marlene Dufresne

Marine Humeau

Mael Chalret du Rieu

Barbara Bournet

Janick Selves

Rosine Guimbaud

Nicolas Carrere

Louis Buscail

Jerome Torrisani

Pierre Cordelier

Affiliations

Soon will be listed here.

Abstract

Despite tremendous efforts from scientists and clinicians worldwide, pancreatic adenocarcinoma (PDAC) remains a deadly disease due to the lack of early diagnostic tools and reliable therapeutic approaches. Consequently, a majority of patients (80%) display an advanced disease that results in a low resection rate leading to an overall median survival of less than 6 months. Accordingly, robust markers for the early diagnosis and prognosis of pancreatic cancer, or markers indicative of survival and/or metastatic disease are desperately needed to help alleviate the dismal prognosis of this cancer. In addition, the discovery of new therapeutic targets is mandatory to design effective treatments. In this review, we will highlight the translational studies demonstrating that microRNAs may soon translate into clinical applications as long-awaited screening tools and therapeutic targets for PDAC.

Citing Articles

Role of microRNAs in response to cadmium chloride in pancreatic ductal adenocarcinoma.

Mortoglou M, Djordjevic A, Djordjevic V, Collins H, York L, Mani K Arch Toxicol. 2021; 96(2):467-485.

PMID: 34905088 PMC: 8837568. DOI: 10.1007/s00204-021-03196-9.

Identification of Serum microRNA-25 as a novel biomarker for pancreatic cancer.

Yu Y, Tong Y, Zhong A, Wang Y, Lu R, Guo L Medicine (Baltimore). 2020; 99(52):e23863.

PMID: 33350781 PMC: 7769376. DOI: 10.1097/MD.0000000000023863.

Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer.

Buscail L, Bournet B, Cordelier P Nat Rev Gastroenterol Hepatol. 2020; 17(3):153-168.

PMID: 32005945 DOI: 10.1038/s41575-019-0245-4.

Present and Future of Endoscopic Ultrasound-Guided Tissue Acquisition in Solid Pancreatic Tumors.

Park J, Lee K Clin Endosc. 2019; 52(6):541-548.

PMID: 31812159 PMC: 6900303. DOI: 10.5946/ce.2019.127.

Role of non-coding RNA in pancreatic cancer.

Lv Y, Huang S Oncol Lett. 2019; 18(4):3963-3973.

PMID: 31579086 PMC: 6757267. DOI: 10.3892/ol.2019.10758.

References

Poplin E, Wasan H, Rolfe L, Raponi M, Ikdahl T, Bondarenko I . Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. J Clin Oncol. 2013; 31(35):4453-61. DOI: 10.1200/JCO.2013.51.0826. View

Iorio M, Croce C . MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 2012; 4(3):143-59. PMC: 3376845. DOI: 10.1002/emmm.201100209. View

Jamieson N, Morran D, Morton J, Ali A, Dickson E, Carter C . MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin Cancer Res. 2011; 18(2):534-45. DOI: 10.1158/1078-0432.CCR-11-0679. View

Zhao G, Zhang J, Liu Y, Qin Q, Wang B, Tian K . miR-148b functions as a tumor suppressor in pancreatic cancer by targeting AMPKα1. Mol Cancer Ther. 2012; 12(1):83-93. DOI: 10.1158/1535-7163.MCT-12-0534-T. View

Campbell P, Yachida S, Mudie L, Stephens P, Pleasance E, Stebbings L . The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010; 467(7319):1109-13. PMC: 3137369. DOI: 10.1038/nature09460. View

Schultz N, Werner J, Willenbrock H, Roslind A, Giese N, Horn T . MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Mod Pathol. 2012; 25(12):1609-22. DOI: 10.1038/modpathol.2012.122. View

Schultz N, Andersen K, Roslind A, Willenbrock H, Wojdemann M, Johansen J . Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer--five microRNAs in a prognostic index. World J Surg. 2012; 36(11):2699-707. DOI: 10.1007/s00268-012-1705-y. View

Liu C, Cheng H, Shi S, Cui X, Yang J, Chen L . MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3. Curr Mol Med. 2013; 13(4):467-78. DOI: 10.2174/1566524011313040001. View

Wang P, Zhang J, Zhang L, Zhu Z, Fan J, Chen L . MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. Gastroenterology. 2013; 145(5):1133-1143.e12. DOI: 10.1053/j.gastro.2013.07.048. View

10.

Zhang Y, Yang J, Cui X, Chen Y, Zhu V, Hagan J . A novel epigenetic CREB-miR-373 axis mediates ZIP4-induced pancreatic cancer growth. EMBO Mol Med. 2013; 5(9):1322-34. PMC: 3799489. DOI: 10.1002/emmm.201302507. View

11.

Zhang S, Hao J, Xie F, Hu X, Liu C, Tong J . Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. Carcinogenesis. 2011; 32(8):1183-9. DOI: 10.1093/carcin/bgr105. View

12.

Nagano H, Tomimaru Y, Eguchi H, Hama N, Wada H, Kawamoto K . MicroRNA-29a induces resistance to gemcitabine through the Wnt/β-catenin signaling pathway in pancreatic cancer cells. Int J Oncol. 2013; 43(4):1066-72. DOI: 10.3892/ijo.2013.2037. View

13.

Sicard F, Gayral M, Lulka H, Buscail L, Cordelier P . Targeting miR-21 for the therapy of pancreatic cancer. Mol Ther. 2013; 21(5):986-94. PMC: 3666633. DOI: 10.1038/mt.2013.35. View

14.

Marin-Muller C, Li D, Bharadwaj U, Li M, Chen C, Hodges S . A tumorigenic factor interactome connected through tumor suppressor microRNA-198 in human pancreatic cancer. Clin Cancer Res. 2013; 19(21):5901-13. PMC: 3920728. DOI: 10.1158/1078-0432.CCR-12-3776. View

15.

Matthaei H, Wylie D, Lloyd M, Dal Molin M, Kemppainen J, Mayo S . miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts. Clin Cancer Res. 2012; 18(17):4713-24. PMC: 3547600. DOI: 10.1158/1078-0432.CCR-12-0035. View

16.

Greither T, Grochola L, Udelnow A, Lautenschlager C, Wurl P, Taubert H . Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer. 2009; 126(1):73-80. DOI: 10.1002/ijc.24687. View

17.

Giovannetti E, van der Velde A, Funel N, Vasile E, Perrone V, Leon L . High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer. PLoS One. 2012; 7(11):e49145. PMC: 3498320. DOI: 10.1371/journal.pone.0049145. View

18.

Kim V, Han J, Siomi M . Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 2009; 10(2):126-39. DOI: 10.1038/nrm2632. View

19.

Bauer A, Keller A, Costello E, Greenhalf W, Bier M, Borries A . Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue. PLoS One. 2012; 7(4):e34151. PMC: 3325244. DOI: 10.1371/journal.pone.0034151. View

20.

Humeau M, Torrisani J, Cordelier P . miRNA in clinical practice: pancreatic cancer. Clin Biochem. 2013; 46(10-11):933-6. DOI: 10.1016/j.clinbiochem.2013.03.019. View